StockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)

StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report released on Tuesday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Arcadia Biosciences in a report on Wednesday, August 21st.

Arcadia Biosciences Price Performance

NASDAQ:RKDA opened at $4.70 on Tuesday. Arcadia Biosciences has a 12 month low of $1.85 and a 12 month high of $5.34. The firm has a market capitalization of $6.41 million, a PE ratio of -0.91 and a beta of 1.34. The business’s fifty day moving average price is $2.98 and its 200 day moving average price is $2.80.

Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. During the same quarter in the previous year, the company posted ($2.64) EPS. As a group, equities analysts anticipate that Arcadia Biosciences will post -1.7 EPS for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.